CSL LIMITED
Underlying profit (NPATA) was
Dr.
'CSL Seqirus achieved solid growth in a challenging season. Its portfolio of differentiated products outperformed the market.
'For CSL Vifor we are well prepared for the transitioning iron market.'
PERFORMANCE
Total revenue was
Immunoglobulin (Ig) product sales of
PRIVIGEN / INTRAGRAM (Immune Globulin Intravenous (Human), 10% Liquid) sales grew 27%3 as the momentum from the prior year continued in improving product availability and patient diagnosis rates.
HIZENTRA (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by patient diagnosis rates. HIZENTRA continues to be the clear market leader for subcutaneous immunoglobulin.
Underlying demand for Ig continues to be strong due to significant patient needs in core indications - namely Primary Immune Deficiency, Secondary Immune Deficiency and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Albumin sales of
Sales were strong in emerging markets with solid growth in the US and
Haemophilia product sales of
IDELVION,
HEMGENIX, the first and only gene therapy for haemophilia B was successfully launched in the US in FY23 and patient referrals have been accelerating.
The haemophilia A market continued to be competitive resulting in a modest decline in sales for AFSTYLA, a novel recombinant factor VIII product.
Plasma-derived haemophilia products, however, achieved growth of 8% driven by HUMATE / HAEMATE, therapies for the treatment of patients with von Willebrand disease.
Specialty products sales of
KCENTRA (4 factor prothrombin complex concentrate) recorded sales growth of 12%3, as it continues to further penetrate the warfarin reversal market in the US.
HAEGARDA, our therapy for patients with Hereditary Angioedema, increased 9%, driven by the continued shift from on-demand to prophylaxis treatment and a strong performance in the
Garadacimab (Anti-FXIIa) for HAE, was filed for regulatory approval in the US and EU.
Plasma Collections
Plasma collections remain strong. The cost of collections, which includes donor compensation and labour, continued to trend down.
A new roll out plan for the RIKA plasmapheresis devices was developed. Deployment across the US fleet is expected over the next 18 months. In addition, results from an individualised nomogram trial conducted by our supplier have been submitted for regulatory approval.
CSL Seqirus
Total revenue of
This growth was achieved against a backdrop of reduced rates of immunisation and highlights the strength of CSL Seqirus' differentiated product portfolio.
During the period: Self-amplifying mRNA vaccine for COVID was approved by
aQIVc, a next generation influenza vaccine combining adjuvant technology with cell-based manufacturing, enrolled its last patient in the Phase III clinical study in
CSL Vifor
Total revenue was
During the period
Preparations were made for the transitioning iron market
There was strong performance from the long-acting erythropoiesis-stimulating agent, MIRCERA
TAVNEOS was successfully launched in multiple European countries
While the strategic potential of the business remains strong, we have dampened our near-term growth aspirations for CSL Vifor.
Expense Performance
Research and development (R&D) expenses were
Selling and marketing expenses (S&M) were
General and administrative (G&A) expenses were
Depreciation and amortisation (D&A) expense (excluding acquired intellectual property) was
Net finance costs were
Financial position
Cashflow from operations was
Cash outflow from investing was
CSL's balance sheet remains in a strong position with net assets of
Current assets increased by 10% to
Non-current assets increased by 1% to
Current liabilities increased by 2% to
Non-current liabilities decreased by 3% to
Contact:
Tel: +61 3 9389 3470
Email: bernard.ronchi@csl.com.au
Tel: +61 402 231 696
Email: stephen.mckeon@csl.com.au
(C) 2024 Electronic News Publishing, source
